PDE5A and cancer: Recently, this cell phenotype has been studied for targeted therapy, and phosphodiesterase 5 (PDE5) inhibition has been proven to reduce MDSCs function in different kinds of cancer as multiple myeloma, head and neck cancer, colon cancer and lymphocyte leukaemia [48].